Syncona Limited (SYNC) - Total Liabilities

Latest as of September 2025: GBX13.77 Million GBX ≈ $1.68K USD

Based on the latest financial reports, Syncona Limited (SYNC) has total liabilities worth GBX13.77 Million GBX (≈ $1.68K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Syncona Limited net asset momentum to track the company's year-over-year net asset growth rate.

Syncona Limited - Total Liabilities Trend (2013–2025)

This chart illustrates how Syncona Limited's total liabilities have evolved over time, based on quarterly financial data. See SYNC free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Syncona Limited Competitors by Total Liabilities

The table below lists competitors of Syncona Limited ranked by their total liabilities.

Company Country Total Liabilities
XOX Bhd
KLSE:0165
Malaysia RM188.00 Million
paragon GmbH & Co. KGaA
F:PGN
Germany €106.61 Million
YKGI Holdings Bhd
KLSE:7020
Malaysia RM153.59 Million
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc
LSE:ATR
UK GBX23.04 Million
UNITEDLABELS Aktiengesellschaft
F:ULC
Germany €25.67 Million
Lite Access Technologies Inc
V:LTE
Canada CA$27.15 Million
Dovre Group Plc
HE:DOV1V
Finland €71.17 Million
Phoenix New Media Limited
NYSE:FENG
USA $506.78 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Syncona Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Syncona Limited.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.02 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.01 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.01 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Syncona Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Syncona Limited (2013–2025)

The table below shows the annual total liabilities of Syncona Limited from 2013 to 2025.

Year Total Liabilities Change
2025-03-31 GBX11.79 Million
≈ $1.44K
-3.47%
2024-03-31 GBX12.22 Million
≈ $1.49K
-11.18%
2023-03-31 GBX13.76 Million
≈ $1.67K
-41.57%
2022-03-31 GBX23.55 Million
≈ $2.86K
-38.23%
2021-03-31 GBX38.12 Million
≈ $4.64K
+25.76%
2020-03-31 GBX30.31 Million
≈ $3.69K
+26.88%
2019-03-31 GBX23.89 Million
≈ $2.91K
+57.33%
2018-03-31 GBX15.18 Million
≈ $1.85K
+148.59%
2017-03-31 GBX6.11 Million
≈ $743.17
+25.04%
2016-03-31 GBX4.88 Million
≈ $594.36
+7.41%
2015-03-31 GBX4.55 Million
≈ $553.36
+30.54%
2014-03-31 GBX3.48 Million
≈ $423.90
+209.69%
2013-03-31 GBX1.12 Million
≈ $136.88
--

About Syncona Limited

LSE:SYNC UK Asset Management
Market Cap
$7.90 Million
GBX64.96 Billion GBX
Market Cap Rank
#27608 Global
#394 in UK
Share Price
GBX106.80
Change (1 day)
+0.38%
52-Week Range
GBX86.90 - GBX109.80
All Time High
GBX302.47
About

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and… Read more